Healthcare U.K. Community

A case for buying shares in AIM: TSTL Tristel currently rests on a combination of recent share-price weakness and improving business fundamentals. The share price has fallen to around GBX 385–390p in mid-March 2026 after trading above GBX 420–430p earlier in the year, leaving it noticeably below its recent range and close to the middle of its 52-week band of roughly GBX 260p–445p.Read more

Craneware sells software that helps U.S. hospitals run and bill more smoothly, but stricter rules and slower rollouts for new AI features could keep profits squeezed in the near term. The upside case rests on whether its growing platform can win more hospitals and expand into new hospital workflows without getting derailed by changes to key government programs.Read more

AOTI bets that insurance coverage opens the door for many more people with hard-to-heal wounds to get its oxygen-based treatment at home, using a nationwide care network it already runs. The big question is whether that coverage change arrives soon enough—and whether payment delays, rising costs, or competitors slow the momentum.Read more

AOTI brings oxygen therapy for hard-to-heal wounds into patients’ homes, and a pending Medicare decision could open the door to far wider access. The key question is whether insurers and health systems embrace this home-based, outcomes-focused approach fast enough—or whether reimbursement delays and rising costs slow the story down.Read more

Smith & Nephew is pushing hard into robotic-assisted surgery, new implants, and wound care products that hospitals use again and again, which could help it win more business as demand for less invasive procedures grows. But changes to healthcare rules and pricing pressure could hit some of its fastest-growing areas, making execution and new product rollouts critical.Read more

Hospitals are moving more of their data and day-to-day paperwork into the cloud and are starting to use AI to reduce time spent on admin tasks, which could make Craneware’s software harder to live without. But if hospital budgets tighten or big customers switch systems, new deals and expansions could slow faster than many expect.Read more

Craneware sells software that helps U.S. hospitals run more smoothly and get paid correctly, and new tools using AI could make its platform more valuable to existing customers. But its fortunes are tied to shifting rules around a key hospital drug-pricing program and to how much cash-strapped hospitals can keep spending on new software.Read more

Inspiration Healthcare Group wants to grow beyond its home markets by selling more neonatal breathing equipment and building up repeat income from services and consumables, but the biggest upside may take longer than investors expect. Regulatory delays, tough hospital buying budgets, and the risk of operational missteps could all keep progress slower and bumpier than the long-term story suggests.Read more

Spire Healthcare could benefit as longer waits in the public system push more people toward private treatment, while upgrades like new technology and streamlined admin aim to make care faster and more efficient. The big question is whether cost pressures, tougher competition, and reliance on public contracts could derail that improvement.Read more